Orphazyme CEO excited for milestone: We are preparing for all scenarios

In Q3, when Orphazyme receives the first phase III results of the main asset arimoclomol, the company will reach a major milestone. This is according to CEO Anders Hinsby, who has confidence in the study but is preparing for all possible scenarios.

Photo: /ritzau/Anne Bæk

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles